According to incomplete statistics from the China Pharmaceutical Equipment Industry Association, pharmaceutical equipment manufacturers from 13 developed countries and 7 foreign pharmaceutical machinery associations, including the United States and Germany, have established representative offices in my country. There are more than 20 solely (jointly) funded pharmaceutical machinery manufacturers in China, and there are more than 200 pharmaceutical machinery manufacturers who are interested in or planning to find Chinese agents. Compared with 2006, the number of foreign-funded enterprises has increased by 5 to 7 times.
The relevant person in charge of the China Pharmaceutical Equipment Industry Association said that in recent years, with the continuous improvement of drug quality standards, my country's pharmaceutical machinery market demand has continued to expand. While the total output value of the domestic pharmaceutical machinery industry has increased significantly, foreign-funded enterprises have also entered in large numbers. A situation of competing on the same field and fighting hand to hand has formed. In the future, the domestic pharmaceutical machinery industry must focus on improving standards, improving self-discipline, and continuously improving core competitiveness.
Recently, the 2012 annual report released by Hunan Qianshan Pharmaceutical Machinery Co., Ltd. showed that last year Qianshan Pharmaceutical Machinery’s main revenue increased by 38.25% year-on-year, and its operating profit increased by 40.14% year-on-year, making it a well-deserved dark horse on the GEM. In fact, the impressive performance is not unique to Qianshan Pharmaceutical Machinery, but a collective characteristic of the pharmaceutical machinery industry.
Data from the China Pharmaceutical Equipment Industry Association shows that in 2012, the product sales revenue of the 277 member units counted by the association was 18.373 billion yuan, three times that of 2006; the total profit was 2.027 billion yuan, 3.6 times that of 2006; exports The delivery value was 2.034 billion yuan, 2.8 times that of 2006. It is conservatively estimated that the industry's output value exceeds 20 billion yuan.
my country's pharmaceutical machinery started in the 1980s. Looking at the development of the past 30 years, the industry has market cyclical characteristics, that is, the development momentum of the pharmaceutical machine market comes from the upgrading of the pharmaceutical industry. According to the person in charge of the above-mentioned association, after 2006, with the basic completion of the 1998 version of pharmaceutical GMP certification, the development of the pharmaceutical machinery industry once hit a low point. However, since 2010, with the implementation of the newly revised pharmaceutical GMP certification, the pharmaceutical machinery market has picked up again. In 2010, the total output value of my country's pharmaceutical industry exceeded the 1 trillion yuan mark, and the output value and profits of the pharmaceutical machinery industry also achieved historic leaps. Leading companies such as Shanghai Tofflon, Shandong Xinhua Medical, and Chutian Pharmaceutical Machinery began to transform from simple mechanical processing manufacturers to professional manufacturers that provide overall equipment engineering solutions, and the industry level has significantly improved.
The development of the pharmaceutical machinery industry in the past five years has shown seven major characteristics: First, remarkable achievements have been made in exploring the international market. Product export is no longer the glory of individual companies, but has become an industry phenomenon. At present, my country's pharmaceutical equipment products are exported to more than 85 countries, with an average annual growth rate of total export delivery value of 23.075%. Eight major categories of products are exported, and engineering contracting projects continue to increase. Shanghai Tofflon and Xinhua Medical are the leaders among them. The second is to attach great importance to patents, and the number of products with independent intellectual property rights has increased rapidly. As of May 20, 2008, my country had a total of 78,024 domestic patents related to pharmaceutical equipment. It is common for a product to have multiple patents. The third is to develop new products and achieve technological innovation based on the requirements of the newly revised pharmaceutical GMP. In particular, sterile drug production equipment has basically replaced imported products, saving pharmaceutical companies a lot of costs. Fourth, the concept of quality by design has been recognized and implemented by many pharmaceutical machinery companies. Providing equipment solutions for pharmaceutical companies that comply with the newly revised pharmaceutical GMP standards and helping pharmaceutical companies reduce quality risks has become the direction of pharmaceutical machinery manufacturing companies. Fifth, pharmaceutical machinery manufacturing enterprises have generally enhanced their awareness of standard strategies, and have actively participated in formulating industry standards. Sixth, the level of enterprise management (implementing ISO9000 standards) has generally improved, and some enterprises have realized the transformation from experience management to scientific management. Seventh, the level of automated online testing of products has been improved.
In 2011, leading domestic pharmaceutical machinery companies Hunan Qianshan Pharmaceutical Machinery and Shanghai Tofflon were successfully listed on the GEM of the capital market. This marked that the pharmaceutical machinery industry has entered the perspective of capital and the investment value has gradually emerged. Truking Technology followed suit and also entered the IPO stage. Zheng Xiaodong, chairman of Tofflon, said that after 30 years of development, pharmaceutical machinery has gradually grown into an independent industry and is increasingly valued by all parties in society. As the country's medical investment continues to increase and the pharmaceutical market expands, the pharmaceutical machinery industry will continue to maintain rapid development.
In recent years, my country's huge medical market has also attracted more and more foreign-funded enterprises to enter, and the curtain of competition between domestic and foreign capital has quietly begun. my country holds two pharmaceutical machinery exhibitions every year, and judging from the exhibition recruitment situation, the number of booths in the International Pavilion for foreign investment has increased from more than 20 at the beginning to 65 this year.
Fu Jianping, general manager of Beijing Shuanghe Pharmaceutical Equipment Co., Ltd., said that my country's pharmaceutical machinery production started late, most of which are imitations, and the gap with foreign-funded enterprises is large. In the past, almost all high-end pharmaceutical equipment used by domestic pharmaceutical companies were imported products and were expensive. Nowadays, domestic pharmaceutical machinery manufacturers are developing rapidly, and a considerable part of high-end equipment has been domestically produced. This has effectively promoted the industrial upgrading of the pharmaceutical industry and saved pharmaceutical companies a lot of money.
Judging from the last National Pharmaceutical Machinery Exhibition, the pace of pharmaceutical machinery technology progress has accelerated significantly. The non-PVC large infusion production automatic line and washing, drying, filling and sealing linkage line exhibited by Changsha Chutian Technology Co., Ltd. can fully meet the sterility requirements of the newly revised pharmaceutical GMP; the DPP400 aluminum plastic foam launched by Beijing Shuanghe Pharmaceutical Equipment Co., Ltd. The hood forming machine has realized full servo control and can continuously complete multiple procedures such as forming → palletizing → cartoning → middle packaging → packing → printing of supervision codes on one production line. It has the same functions as imported equipment; Shanghai Tofflon Technology Co., Ltd. has launched solutions and solutions in the fields of freeze-drying process research, clean air-conditioning design and practice, aseptic isolation and hydrogen peroxide sterilization technology, and fully automatic liquid dispensing systems during the implementation of the newly revised pharmaceutical GMP for more than a year. Equipment, domestic freeze-drying machines have occupied more than 80% of the market share...
The person in charge of the above-mentioned association said that in recent years, there are two main reasons for the downward trend in the share of imported equipment in the domestic market: first, the quality of domestic machinery is gradually approaching that of foreign equipment and the manufacturing cycle is short; second, domestic machinery is more cost-effective. For example, a set of Shuanghe's follow-up packaging production line sells for RMB 5 to 6 million, while the same equipment from Uman Company sells for RMB 15 million, which is three times the price of domestic equipment. Last year, almost all of the sterile companies that took the lead in passing the newly revised pharmaceutical GMP certification tended to purchase domestic equipment.
It is understood that in the past, compared with foreign-invested products, domestic pharmaceutical machinery not only had a rough appearance and low automation level, but also lacked humanization. In recent years, pharmaceutical companies have gradually realized that "product quality is produced, not inspected." Pharmaceutical machinery is crucial, so they have put forward higher requirements for equipment. Many pharmaceutical machinery manufacturers have also begun to consider the quality standards of pharmaceutical companies, developed dynamic monitoring systems, fully enclosed automatic production lines, etc., and added humanized designs such as warning signs to the equipment.
In 2010, the General Administration of Quality Supervision and Quarantine officially resumed random inspections of the quality of pharmaceutical equipment products. This is the result of the efforts and appeals of the China Pharmaceutical Equipment Industry Association.
In 1998, the former State Administration of Medicine was revoked, and the licensing system for pharmaceutical equipment products and the state's inspection of product quality were also discontinued. However, in the subsequent period, some pharmaceutical machinery manufacturers had weak quality awareness. Not only were they unable to consciously and strictly implement product standards, they also ignored patents, copied excellent domestic products, and competed at low prices. Such products look similar in appearance but not in spirit. After entering the market, they not only disrupt the normal order of my country's pharmaceutical equipment market, but also cause serious losses to pharmaceutical companies, and are not conducive to the technological progress of the industry. Many pharmaceutical companies and pharmaceutical machinery manufacturers are eager for the state to implement licensing and product quality inspection systems for pharmaceutical equipment products to standardize market order. To this end, the China Pharmaceutical Equipment Industry Association reported and communicated with the State Administration of Quality Supervision and Quarantine many times, and submitted the "Report on Requesting the Resumption of National Supervision and Spot Inspection of Pharmaceutical Equipment Products" to the State Administration of Quality Supervision and Quarantine. The country finally resumed the inspection in 2010. National inspection.
Inspection is inseparable from standards. At present, the standard level of the domestic pharmaceutical machine industry is relatively low. There are only 182 published pharmaceutical machine standards. There is a certain gap between the compatibility and coverage of the standards and the requirements of industry development. Moreover, because industry standards are not mandatory, pharmaceutical machinery production The business is not executing ideally. With the internationalization of competition in the pharmaceutical machinery market, this problem has become increasingly prominent. It can be said that the standard level of pharmaceutical machinery has determined its market position.
To this end, the China Pharmaceutical Equipment Industry Association has established the improvement of pharmaceutical machinery standards as its focus, and is currently stepping up the formulation of the "Twelfth Five-Year Plan for the Construction of Technical Standard System for the Pharmaceutical Equipment Industry". It is expected that there will be more than 40 pharmaceutical machinery in the next three years. Standard formulation completed.
The person in charge of the association said that the China Pharmaceutical Equipment Industry Association attaches great importance to standard setting and industry self-discipline, and patent infringing companies are strictly prohibited from participating in every exhibition. Once a company's patent infringement is discovered, a warning letter will be issued to inform it of its negative impact. In order to help companies safeguard their rights, the association has begun to cooperate with professional law firms to help companies resolve patent drafting and patent disputes. "Now large pharmaceutical machinery companies have gradually realized the importance of setting standards, and the enthusiasm of companies to participate in standard setting has greatly increased. We believe that the future of the pharmaceutical machinery industry will be better." said the person in charge of the above-mentioned association. (Source: China Medical News)
